![]() |
|
|
Vol. 295, Issue 3, 927-933, December 2000
Department of Biomedical Sciences (S.Z., G.S.), Callerio
Foundation-Onlus, Trieste, Italy (A.B., M.C., A.S., B.G., G.S.); and
Department of Chemical Sciences, University of Trieste, Trieste, Italy
(E.A., E.I.)
The ruthenium complexes
trans-dichlorotetrakisdimethylsulfoxide ruthenium(II)
(trans-Ru), imidazolium
trans-imidazoletetrachlororuthenate (ICR), sodium
trans-tetramethylensulfoxideisoquinolinetetrachlororuthenate (TEQU), and imidazolium
trans-imidazoledimethylsulfoxidetetrachlororuthenate (NAMI-A) are tested in vitro by short exposure of MCF-7, LoVo, KB, and
TS/A tumor cells to 10
4 M concentration, and in vivo on
Lewis lung carcinoma by a daily i.p. treatment for 6 consecutive days
using equitoxic and maximum tolerated doses. NAMI-A 1) inhibited tumor
cell invasion of matrigel, 2) induced a transient accumulation of cells
in the G2-M phase, 3) did not modify in vitro cell growth,
and 4) markedly reduced lung metastasis formation. TEQU showed
significant cytotoxicity in vitro and was not antimetastatic in vivo.
ICR and trans-Ru did not modify cell cycle distribution
of in vitro tumor cells nor did they inhibit matrigel invasion; ICR was
also devoid of antimetastasis effects in vivo. Ruthenium uptake by
tumor cells did account for in vitro cytotoxicity but not for other in
vitro actions or for in vivo antimetastasis activity. The contemporary absence of cytotoxicity, associated to inhibition of matrigel crossing
and to transient block in the premitotic G2-M phase, appears to be prerequisites for a ruthenium compound to show in vivo-selective antimetastasis effect. The validation of this model for
other classes of compounds will allow an understanding of the combined
weight of the above-mentioned phenomena for tumor metastasis growth and control.
This article has been cited by other articles:
![]() |
B. Gava, S. Zorzet, P. Spessotto, M. Cocchietto, and G. Sava Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 284 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Rademaker-Lakhai, D. van den Bongard, D. Pluim, J. H. Beijnen, and J. H. M. Schellens A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent Clin. Cancer Res., June 1, 2004; 10(11): 3717 - 3727. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bouma, B. Nuijen, E. E Challa, G. Sava, A. Flaibani, A. Bult, and J. H Beijnen Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its hemolytic potential Journal of Oncology Pharmacy Practice, March 1, 2004; 10(1): 7 - 15. [Abstract] [PDF] |
||||
![]() |
A. Bergamo, G. Stocco, B. Gava, M. Cocchietto, E. Alessio, B. Serli, E. Iengo, and G. Sava Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 725 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sava, S. Zorzet, C. Turrin, F. Vita, M. Soranzo, G. Zabucchi, M. Cocchietto, A. Bergamo, S. DiGiovine, G. Pezzoni, et al. Dual Action of NAMI-A in Inhibition of Solid Tumor Metastasis: Selective Targeting of Metastatic Cells and Binding to Collagen Clin. Cancer Res., May 1, 2003; 9(5): 1898 - 1905. [Abstract] [Full Text] [PDF] |
||||